$NTRA

Chapman Steven Leonard sold $323K of NTRA

Chapman Steven Leonard (CEO AND PRESIDENT) sold 1,443 shares of Natera, Inc. (NTRA) at $223.91 ($0.32M total) on 2026-06-04 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Chapman Steven Leonard
Published Jun 6, 2026, 1:05 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 6, 2026, 1:33 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$NTRA
Neutral
medium confidence
Mentioned
$NTRA
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

The disclosure can influence short-term sentiment and positioning, but it does not introduce new operational/financial information about Natera.

02

Market read

A scheduled insider sale is typically a low-signal event; any price reaction is likely limited and sentiment-driven.

03

What to watch

Traders may overreact to single insider sales; the key is whether there is a pattern of consecutive sales outside 10b5-1 or accompanied by other fundamental disclosures (not present here).

Relevance 6/10Novelty 3/10Timing: Filed 2026-06-05 for a sale executed 2026-06-04

Background

The article is an SEC Form 4 insider transaction disclosure for Natera, showing an officer/director sale executed under a Rule 10b5-1 plan.

Company-level read

Ticker impact

$NTRANeutralMedium confidence
Context

Natera CEO and President Chapman Steven Leonard sold $323.1K of NTRA shares via an open-market transaction disclosed on Form 4.

Expected impact

Low-to-moderate short-term downside bias possible, but likely limited given 10b5-1 pre-arrangement.

Evidence & confidence

The filing is a routine insider transaction datapoint; the article provides no new fundamentals, and explicitly notes a pre-arranged 10b5-1 plan, which typically reduces interpretive weight.

Market effects

Minimal; this is company-specific insider activity with no stated sector/regulatory trigger.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.

Key entities

  • Natera, Inc.

    Subject of the SEC Form 4 insider sale by its CEO/president.

  • Chapman Steven Leonard

    CEO and President who sold 1,443 shares at ~$223.91 under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTRAMed

Billionaire Stanley Druckenmiller Bought Amazon and Alphabet in Q2. But His Single Biggest Holding Is Neither of Them -- and It's Not Nvidia Either.

Billionaire investor Stanley Druckenmiller's largest Q2 holding was Natera (NTRA), a genetic testing company, not Amazon or Alphabet. Natera reported Q2 2026 revenue of $752.8M, up 39% YoY, and raised full-year guidance to $2.85B-$2.91B. The company's Signatera cancer detection test is a key growth driver, with FDA, PMDA, and EU approvals.

$NTRAMedAI 8/10

Natera (NTRA) Q2 2026 Earnings Call Transcript

Natera (NTRA) reported Q2 2026 revenue of $752.8 million, up 37.7% year over year, and net loss per diluted share of ($0.47), improved from ($0.74). Total tests processed rose 22.4% to 1,043,900. The company raised full-year revenue guidance to $2.85 billion to $2.91 billion and cited FDA and PMDA approvals for Signatera.

$NTRAHighAI 9/10

Natera Stock Jumps After Q2 Beat And Guidance Hike

Natera Inc. (NTRA) shares rose about 20.9% after Q2 results and guidance. Q2 revenue was $752.8M versus $661.2M consensus, with a Q2 loss of $0.47 per share versus $0.49 expected. Full-year 2026 revenue guidance was raised to $2.85B to $2.91B. The Signatera test was submitted to Japan’s PMDA for muscle-invasive bladder cancer.